Vaxart Inc Stock Price, News & Analysis

Vaxart reported positive developments in its oral vaccine platform during the third quarter of 2022, including encouraging Phase II results for its COVID-19 candidate, demonstrating both serum and mucosal immunity.

The company ended the quarter with $114.8 million in cash but posted a net loss of $29.3 million, up from $17.6 million year-over-year, primarily due to increased R&D costs. With promising data in norovirus trials and key milestones expected in 2023, Vaxart aims to address significant market opportunities.

Vaxart, Inc. (NASDAQ: VXRT) will report its third-quarter financial results on November 8, 2022, after market close. A conference call will follow at 4:30 p.m. ET, where senior management will discuss the company's updates. Vaxart is focused on developing oral recombinant vaccines that can be delivered via tablets, aiming to provide alternatives for various viral infections, including COVID-19, norovirus, seasonal influenza, and RSV. Their innovative delivery platform reduces risks associated with traditional vaccinations, and the company has pending patent applications for its technology.

Vaxart, Inc. (Nasdaq: VXRT) announced that Dr. Sean Tucker and Dr. James Cummings will present at the World Vaccine Congress Europe 2022 in Barcelona on October 13. Dr. Tucker will discuss nasal mucosal responses to a SARS-CoV-2 oral tablet vaccine at 11:30 a.m. CET, while Dr. Cummings will present findings on immune responses to norovirus G1.1 in elderly subjects at 12:00 p.m. CET. Vaxart develops oral recombinant vaccines aimed at various viruses, emphasizing delivery without refrigeration and eliminating needle-stick risks.

Vaxart, Inc. (Nasdaq: VXRT) has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will feature key executives including CEO Andrei Floroiu, CSO Dr. Sean Tucker, and CMO Dr. James Cummings, and will be available for viewing on the Company’s Events page starting September 12 at 7:00 a.m. ET. Vaxart specializes in developing oral recombinant vaccines, aiming to create accessible, needle-free vaccination options for various diseases.

Vaxart, Inc. (NASDAQ: VXRT) announced positive top-line results from the Phase II study of its COVID-19 oral vaccine candidate, VXA-CoV2-1.1-S. The study achieved primary safety and secondary immunogenicity endpoints, showing significant increases in serum neutralizing antibodies, particularly in subjects previously vaccinated with mRNA. Approximately 50% of participants exhibited cross-reactive mucosal responses to Omicron variants. Vaxart aims to advance new vaccine constructs for clinical trials by mid-2023, highlighting the potential for an effective oral COVID-19 vaccine.

Vaxart, Inc. (Nasdaq: VXRT) announced the release of top-line data from the first part of its two-part COVID-19 Phase II trial for its Wuhan S-only construct, scheduled for September 1, 2022. The company will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the findings. Interested analysts and investors can participate via designated phone lines. Vaxart is focused on developing oral recombinant vaccines, with a range of programs aimed at various viral diseases, leveraging its innovative tablet delivery platform.

Vaxart, Inc. (NASDAQ: VXRT) has appointed Dr. Ray Stapleton as its Chief Technology Officer (CTO), effective immediately. With over 20 years of experience, Dr. Stapleton previously worked at Genocea, focusing on personalized immunotherapies. Vaxart's CEO, Andrei Floroiu, expressed confidence in Dr. Stapleton's ability to enhance the company's oral vaccine development efforts. Dr. Stapleton has a strong background in manufacturing operations, having held significant roles at Merck and American Type Culture Collection. Vaxart is developing innovative oral vaccines for various diseases, aiming to change global vaccination methods.

Vaxart, Inc. (NASDAQ: VXRT) announced the appointment of Elaine J. Heron, Ph.D., to its Board of Directors, effective August 25, 2022. With extensive experience in life sciences, Dr. Heron has held various leadership roles, including CEO of Amplyx Pharmaceuticals and Labcyte Inc. Heron replaces Dr. Julie Cherrington, who stepped down from the board. Dr. Heron will contribute to the Science and Technology and Audit Committees, bringing valuable insights to Vaxart's strategic direction as it develops oral vaccines targeting diseases such as coronavirus and RSV.

Vaxart, Inc. (NASDAQ: VXRT) reported progress in its COVID-19 and norovirus vaccine programs in its second quarter update on August 8, 2022. They are developing vaccine candidates targeting omicron variants and expect top-line Phase II COVID-19 data in Q3 2022. The company ended Q2 with $131.5 million in cash, down from $157.0 million, and reported a net loss of $29.4 million. R&D expenses surged to $19.9 million, reflecting increased investments in vaccine development. The company aims to select COVID-19 constructs in Q4 2022 and start new trials in 2023.